The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021.
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021.
复制标题
DOI：
10.1002/cac2.12193
复制
发表时间：
2021-08
期刊：
影响因子：
--
通讯作者：
Xu RH
中科院分区：
文献类型：
--
作者：
Wang FH;Zhang XT;Li YF;Tang L;Qu XJ;Ying JE;Zhang J;Sun LY;Lin RB;Qiu H;Wang C;Qiu MZ;Cai MY;Wu Q;Liu H;Guan WL;Zhou AP;Zhang YJ;Liu TS;Bi F;Yuan XL;Rao SX;Xin Y;Sheng WQ;Xu HM;Li GX;Ji JF;Zhou ZW;Liang H;Zhang YQ;Jin J;Shen L;Li J;Xu RH
东西方胃癌患者在流行病学特征、临床病理特征、肿瘤生物学特征、治疗方式、药物选择等方面存在差异。中国临床肿瘤学会（CSCO）自2016年起组织了由胃癌各亚专科资深专家组成的专家组，编制了胃癌诊疗临床指南，并每年更新一次。这些专家考虑到地区差异，在充分考虑诊疗资源可及性的情况下，对相关证据进行专家共识判断，并对胃癌临床诊疗提出了不同等级的建议，以体现癌症治疗的价值，满足中国的健康经济指标。《2021年CSCO胃癌临床实践指南》涵盖了胃癌的诊断、治疗、随访和筛查。本次更新的指南以2020年版CSCO中国胃癌指南为基础，整合了过去一年国内外主要临床研究的结果，重点纳入了来自中国人群的研究数据，以提供更加个性化和临床相关的建议。对于非转移性胃癌的综合治疗，重视新辅助治疗。围手术期化疗的价值逐渐清晰，其推荐水平也不断更新。对于转移性胃癌的综合治疗，包括免疫治疗的建议，并提供了免疫检查点抑制剂从三线到一线治疗不同患者组的详细说明。中国临床肿瘤学会（CSCO）于2016年组织了胃癌各亚专科的资深专家小组，编制了胃癌临床指南，并每年更新一次。《2021年CSCO胃癌临床实践指南》涵盖了胃癌的诊断、治疗、随访和筛查。
There exist differences in the epidemiological characteristics, clinicopathological features, tumor biological characteristics, treatment patterns, and drug selections between gastric cancer patients from the Eastern and Western countries. The Chinese Society of Clinical Oncology (CSCO) has organized a panel of senior experts specializing in all sub‐specialties of gastric cancer to compile a clinical guideline for the diagnosis and treatment of gastric cancer since 2016 and renews it annually. Taking into account regional differences, giving full consideration to the accessibility of diagnosis and treatment resources, these experts have conducted expert consensus judgment on relevant evidence and made various grades of recommendations for the clinical diagnosis and treatment of gastric cancer to reflect the value of cancer treatment and meeting health economic indexes in China. The 2021 CSCO Clinical Practice Guidelines for Gastric Cancer covers the diagnosis, treatment, follow‐up, and screening of gastric cancer. Based on the 2020 version of the CSCO Chinese Gastric Cancer guidelines, this updated guideline integrates the results of major clinical studies from China and overseas for the past year, focused on the inclusion of research data from the Chinese population for more personalized and clinically relevant recommendations. For the comprehensive treatment of non‐metastatic gastric cancer, attentions were paid to neoadjuvant treatment. The value of perioperative chemotherapy is gradually becoming clearer and its recommendation level has been updated. For the comprehensive treatment of metastatic gastric cancer, recommendations for immunotherapy were included, and immune checkpoint inhibitors from third‐line to the first‐line of treatment for different patient groups with detailed notes are provided. The Chinese Society of Clinical Oncology (CSCO) organized a panel of senior experts specializing in all sub‐specialties of gastric cancer to compile the clinical guideline for gastric cancer in 2016 and then renewed it every year. The 2021 CSCO Clinical Practice Guidelines for gastric cancer covered the diagnosis, treatment, follow‐up and screening.
登录
查看更多内容
影响因子：
51.1
作者：
Cats, Annemieke;Jansen, Edwin P. M.;Verheij, Marcel
通讯作者：
Verheij, Marcel
影响因子：
45.3
作者：
Ajani, JA;Mansfield, PF;Gunderson, LL
通讯作者：
Gunderson, LL
影响因子：
3.7
作者：
Badgwell, Brian;Cormier, Janice N.;Mansfield, Paul
通讯作者：
Mansfield, Paul
影响因子：
3.8
作者：
Biondi, A.;D'Ugo, D.;Persiani, R.
通讯作者：
Persiani, R.
影响因子：
45.3
作者：
Al-Batran, Salah-Eddin;Hartmann, Joerg Thomas;Jaeger, Elke
通讯作者：
Jaeger, Elke